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Background: B-cell leukemia 3 (Bcl-3) is a member of the inhibitor of κB family, which regulates a wide range of
biological processes by functioning as a transcriptional activator or as a repressor of target genes. Elevated expression,
sustained nuclear accumulation, and uncontrolled activation of Bcl-3 causes increased cellular proliferation or survival,
dependent on the tissue and type of stimuli.
Methods: We retrospectively reviewed patients who were diagnosed with colorectal cancer at Skåne University
Hospital in Malmö between 1st of January 1990 and 31st of December 1991. Bcl-3 localization in colorectal cancer
was assessed by immunohistochemistry on tissue microarray and freshly isolated colon from patients. Correlation
between Bcl-3 localization and clinicopathological parameters of the cohort were evaluated using the Spearman
rank-order correlation coefficient. In addition, Bcl-3 expression and localization in colon adenocarcinoma cells were
analysed by western blot, immunohistochemistry and subcellular fractionation separately.
Results: We found that Bcl-3 was mainly localized in the cytoplasm in the tumour tissue isolated from colon
cancer patients. Normal colon samples from the same patients showed Bcl-3 localization in the nucleus. In three
out of six colon cancer cell lines, we detected elevated levels of Bcl-3. In these cell lines Bcl-3 was accumulated in
the cytosol. We confirmed these findings by analysing Bcl-3 localization in a colon tissue micro array consisting of
270 cases. In these samples Bcl-3 localization correlated with the proliferation marker Ki-67, but not with the
apoptotic marker Caspase 3.
Conclusion: These findings indicate that analysis of the subcellular localization of Bcl-3 could be a potential-early
diagnostic marker in colon cancer.
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Colorectal cancer (CRC) is the third most common fatal
cancer and its incidence increases with age. Early detec-
tion, adequate surgical excision and optimal adjuvant
treatment are of critical importance for outcome [1]. In
most cases, CRC has a long incubation time, and as the
transformation from healthy tissue to cancerous tissue
could take a long time there is an increased risk for
elderly patients [2]. The clinical stage of the cancer is
determined using the TNM staging system, where T
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unless otherwise stated.metastatic stage. N-stage discriminates between stage II
and stage III disease, whereas positive M-status automat-
ically places the patient into the stage IV category [3].
B-cell leukemia 3 (Bcl-3) was originally identified as a
gene involved in the recurring chromosomal transloca-
tion t (14; 19), which is found in patients with chronic
lymphocytic leukemia [4]. Bcl-3 is largely a nuclear pro-
tein and an atypical inhibitor of κB (IκB) that does not
sequester nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) in the cytoplasm. Instead, Bcl-3
binds to target genes by binding directly to promoter-
bound homodimers of nuclear factor NF-kappa-B p50
subunit (p50) or nuclear factor NF-kappa-B p52 subunit
(p52) and subsequently induces either transactivation or
repression of target gene [5]. Bcl-3 together with p50 cantral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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own transcription levels [6]. Since the discovery that Bcl-3
is an oncogene involved in leukemia, we and others have
determined that Bcl-3 also functions as an oncogene in
solid tumours including breast [7], nasopharyngeal [8],
endometrial carcinomas [9], colorectal cancer [10], and
prostate cancer [11].
High Bcl-3 expression has also been detected in mel-
anoma and other types of skin cancer, such as basal cell
carcinoma and cylindroma [12-14]. Recently, Cogswell
et al. [7] showed that breast tumour tissue contained
significantly more nuclear Bcl-3 compared to the adja-
cent tissue. Later, it was shown that mice overexpressing
NF-κB family member c-Rel proto-oncogene protein
(c-Rel) under the MMTV promoter developed mam-
mary gland tumours that had elevated levels of p50,
p52, nuclear factor NF-kappa-B p65 subunit (p65), V-
Rel avian reticuloendotheliosis viral oncogene homolog
B (RelB) and Bcl-3 in the nucleus [15]. Another onco-
genic property of Bcl-3 is the ability to promote cell
survival in cancer cells [16]. The tumour suppressor
protein p53 (p53) is an important regulator of cell
survival and apoptosis. DNA damage can induce p53 ac-
tivity and subsequently trigger the apoptotic programme.
Under normal conditions the E3-ligase mouse double
minute protein 2 (Mdm2) ubiquitinates p53, leading to
degradation in the proteasome. The Mdm2 promoter
contains a NF-κB binding site and Bcl-3 is required to
activate its expression. When Bcl-3 is overexpressed in
breast cancer cell lines, it can inhibit DNA damage-
induced p53 activity, resulting in increased survival
[17]. Bcl-3 can be localized both in the cytosol or nu-
clei depending on the cell type or stimuli. One example
is the activation of keratinocytes with 12-O-tetradecanoyl-
phorbol-13-acetate (TPA), which induces the nuclear
translocation of Bcl-3. The inhibitory action of Bcl-3 nu-
clear translocation is executed by the tumour suppressor
protein cylindromatosis (CYLD), which can bind directly
to Bcl-3 and prevent its nuclear localization [13].
In the present study, we investigated the early diagnostic
value of the subcellular localization of Bcl-3 in CRC. We
found that Bcl-3 is mainly localized in the cytoplasm in
cancer tissues while nuclear localization of Bcl-3 was de-
tected in non-cancerous tissue. These results were con-
firmed by analysing Bcl-3 localization in colon cancer
specimens and normal colon tissue obtained from 270
patients. Furthermore, we found that Bcl-3 localization
correlated with the proliferation marker Ki-67.
Methods
Patient material, tissue microarray construction and
immunohistochemistry
Colon cancer specimens and normal colon tissue were
obtained from 270 patients who were surgically treatedfor colorectal cancer at Skåne University Hospital in
Malmö between 1st January 1990 and 31st December
1991. The cohort has been described in detail previously
[18,19]. All specimens were histopathologically re-
evaluated on haematoxylin and eosin stained slides and
representative areas were marked prior to tissue micro-
array (TMA) construction. Duplicates of 1.0 mm cores
from each tumour, as well as areas containing normal
colon tissue from 70 of the included patients, were
taken and placed in a recipient block using a semi-
automated arraying machine (TMArrayer, Pathology
Devices, Westminster, MD, USA). Approval was ob-
tained from the Ethics committee at Lund University
(Ref no 445–07) whereby the committee waived the
need for consent other than by the option to opt out.
Prior to immunohistochemical staining, 4 μm thick
TMA sections were mounted onto glass slides and
deparaffinized followed by antigen retrieval using Dako’s
PTLink (DAKO, Glostrup, Denmark). Bcl-3 (C-14: sc-
185 from Santa Cruz) and cleaved-Caspase-3 (ASP175
from Cell Signaling, Antibody #9661) were detected by
immunohistochemistry using Dako’s Autostainerplus
with the EnVisionFlex High pH-kit (DAKO). The per-
centage of positively stained tumour nuclei (%), the
intensity of the nuclear staining (scored 0–4), and the
intensity of Bcl-3 in the cytoplasm (scored 0–3) were
evaluated. All immunohistochemistry scoring was per-
formed by a research associate and a pathologist without
knowledge of pathological and clinical data. Spearman’s
rank-order correlation coefficient was used to examine
the statistical significance of correlations between Bcl-3
expression and other variables. All statistical tests were
two sided and the calculations were done in IBM SPSS
Statistics version 20.0 (IBM, Armonk, NY).
Cell culture
All cell lines were obtained from ATCC. Colon cancer
cell lines HCT-116 and HT-29 were cultured in McCoy’s
5A medium, while SW-48 and SW-480 cells were
maintained in RPMI 1640 medium. LOVO cells were
cultured in F-12 Kaighn’s modification media, CACO-2
cells were maintained in DMEM medium and RKO cells
in MEM medium. All media were supplemented with 10%
fetal bovine serum (Invitrogen), 100 IU/ml penicillin, and
100 μg/ml streptomycin (both Gibco). All cell lines were
cultured at 37°C in a humidified atmosphere containing
5% CO2.
Immunoblotting
Cells were placed on ice and the media were aspirated.
The cells were washed once with cold phosphate-buffered
saline (PBS) and harvested in cold 1 × lysis buffer [50 mM
Tris–HCl (pH 7.4), 150 mM NaCl, 1% Triton-100, con-
taining 40 μl/mL complete protease inhibitors (Roche
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at 12 000 × g for 10 min at 4°C and the protein content
was determined. Equal amounts of protein were electro-
phoretically separated on 10% SDS/polyacrylamide gels
and proteins were transferred onto Immobilion-FL PVDF
membranes (Millipore). Membranes were blocked with
5% non-fat milk in PBST for 1 hour at room temperature
followed by overnight incubation at 4°C with primary
antibodies against Actin (1:40000 MP Biomedicals), α-
tubulin (1:4000 Abcam), Lamin B (1:1000 Santa Cruz),
Bcl-3 (1:500 Santa Cruz). Primary antibodies were de-
tected with horseradish peroxidase-labelled secondary
antibody (1:5000, DAKO). The chemoluminescence was
detected with a charge-coupled device camera (Fujifilm).
Immunofluorescence
Caco-2 cells were cultured on glass cover slips, rinsed
twice with PBS and fixed for 4 min using 4% parafor-
maldehyde in PBS, followed by permeabilization using
0.25% Triton-× 100 in PBS for 10 minutes. After
permeabilization, the cells were washed three times in
PBS and blocked in 1% Bovine Serum Albumin (BSA)
in PBS for 1 hour. Cells were thereafter incubated for
1 h with primary antibody in PBS followed by washing
and incubation with Alexa Fluor 546-conjugated anti-
bodies (Molecular Probes) in PBS. Cover slips were
mounted on object slides in vectashield with diamidino-2-
phenylindole (DAPI) (vector Laboratories). Images were
captured using a 40× oil objective and Zeiss LSM 710
confocal system.
Cell fractionation
In order to separate the cytoplasmic and nuclear fraction
of the colon cancer cells they were first lysed using a less
stringent Buffer A (10 mM HEPES pH7.9, 10 mM KCl










Figure 1 Localization of Bcl-3 in normal colon tissue and in colon cancer.
(upper and middle panels). Immunohistochemistry staining of colorectal tu
peptide (p-C14; Santa Cruz) in a concentration ratio 1:5 (Lower panels).PMSF) on ice for 15 minutes followed by centrifugation
at 6800xg for 2 minutes. The supernatant containing the
cytoplasmic fraction was collected and the pellet washed
in Buffer A followed by centrifugation. Washing was
repeated four times. Cell pellets were resuspended in
more stringent lysis Buffer C (20 mM HEPES pH 7.9,
80 mM NaCl, 1 mM EDTA and EGTA pH 8.0, 1 mM
DTT, 1 mM PMSF) and samples were sonicated twice
for 20 seconds. Both the cytoplasmic and nuclear frac-
tions were then centrifuged at 14000×g for 20 minutes.
Results
Nuclear localization of Bcl-3 has been reported as an in-
dicator for cell proliferation in different types of cancer
[13,15,20]. In the present study, we investigated whether
nuclear localization of Bcl-3 in colon cancer has any
prognostic value. Surprisingly, we found an accumulation
of Bcl-3 in the cytoplasm of colon cancer tissue freshly
isolated from three patients. In contrast Bcl-3 was local-
ized in the nucleus of normal tissues (Figure 1). Staining
of freshly isolated tumour tissue using an antibody against
Bcl-3 with corresponding blocking peptide in a concentra-
tion ratio 1:5 demonstrated the specificity of Bcl-3 anti-
body for immunohistochemistry staining (Figure 1).
Next, immunohistochemical staining of Bcl-3 was per-
formed in tumours from a patient cohort of 270 CRC
patients. Evaluation of the nuclear fraction of Bcl-3 posi-
tive cells (estimated in percent), the nuclear intensity
(scored 0–4, Figure 2) and the cytoplasmic intensity
(scored 0–3, Figure 2) was possible in 264 of 270 (98%)
tumour specimens and in 64 of 70 (91%) cases of normal
colon tissue (Table 1). The excluded cases were either
lost in the staining process or lacked malignant cells in
the core biopsy. In 92% of the normal samples 76–100%
of all nuclei were positive for Bcl-3 compared to only 33%







Bcl-3 staining of normal and colorectal tumours from three patients
mours using an antibody against Bcl-3 with corresponding blocking
Figure 2 Immunohistological staining of Bcl-3 in colon cancer tissue (A-E) and normal colon tissue (F). Nuclear intensity (NI) was scored 0–4,
nuclear fraction (NF) was estimated in percent (%) and cytoplasmic intensity (CI) was denoted by scores between 0–3. (A) NI = 0, NF = 0, CI = 1.
(B) NI = 1, NF = 50%, CI = 2. (C) NI = 2, NF = 50%, CI = 2. (D) NI = 3, NF = 100%, CI = 3. (E) NI = 4, NF = 100%, CI = 2. (F) Representative image of
normal colon tissue, NI = 4, NF = 100%, CI = 1. 20× magnification.
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not the cytoplasmic intensity of Bcl-3 (Table 1). We found
no significant correlation regarding the cytoplasmic inten-
sity of Bcl-3 in normal tissue and tumours (Table 2),
whereas a significant correlation between the nuclearTable 1 Bcl3 expression in normal colon tissue and invasive c
Variable Normal tissue

















†Correlations were calculated using Spearman’s ρ (two-sided). P values were not adfraction of positive cells and the nuclear staining intensity
(Spearman’s ρ = 0.512, p < 0.001) was detected (Table 2).
We next investigated the associations between the nu-
clear fraction of Bcl-3 positive cells and clinicopathologi-
cal parameters in the CRC tumours (Table 2). A negativeolon cancer
Invasive tumour
N = 264 (%) r P†













justed for multiple testing.
Table 2 Association between nuclear fraction of Bcl3 and clinicopathological parameters
Bcl3 nuclear fraction
Variable 0-25% 26-50% 51-75% 76-100% r P†
N (%) 108 (41) 48 (18) 20 (8) 88 (33)
Age
≤75 59 (55) 30 (63) 10 (50) 48 (55) 0.004 0.948
>75 49 (45) 18 (37) 10 (50) 40 (45)
Gender
Female 55 (51) 25 (52) 9 (45) 44 (50) 0.012 0.848
Male 53 (49) 23 (48) 11 (55) 44 (50)
Tumour stage
T1 8 (8) 2 (4) 0 (0) 10 (11,5) −0.097 0.118
T2 22 (20) 15 (33) 4 (21) 26 (30)
T3 63 (59) 26 (57) 12 (63) 41 (47)
T4 14 (13) 3 (6) 3 (16) 10 (11,5)
Node stage
N0 60 (56) 34 (74) 10 (53) 64 (75) −0.159 0.011
N1 29 (27) 10 (22) 7 (37) 14 (16)
N2 18 (17) 2 (4) 2 (10) 8 (9)
Differentiation grade
High 9 (8) 2 (4) 0 (0) 10 (11) −0.045 0.468
Intermediate 67 (62) 37 (77) 15 (75) 55 (63)
Low 32 (30) 9 (19) 5 (25) 23 (26)
Ki67 nuclear fraction
0-25% 8 (8) 6 (13) 0 (0) 3 (4) 0.186 0.003
26-50% 15 (14) 4 (8) 1 (5) 4 (5)
51-75% 35 (33) 13 (27) 4 (20) 24 (28)
76-100% 48 (45) 25 (52) 15 (75) 53 (63)
Bcl3 nuclear intensity
0 (absent) 44 (41) 0 (0) 0 (0) 0 (0) 0.512 <0.001
1 6 (5) 6 (13) 1 (5) 4 (5)
2 33 (31) 16 (33) 2 (10) 19 (22)
3 19 (18) 22 (46) 12 (60) 48 (54)
4 6 (5) 4 (8) 5 (25) 17 (19)
Bcl3 cytoplasmic intensity
0 (absent) 5 (5) 1 (1) 0 (0) 1 (1) 0.190 0.002
1 55 (51) 20 (42) 8 (40) 30 (34)
2 38 (35) 19 (40) 7 (35) 42 (48)
3 10 (9) 8 (17) 5 (25) 15 (17)
†Correlations were calculated using Spearman’s ρ (two-sided). P values were not adjusted for multiple testing.
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with the nuclear fraction of the proliferation marker Ki67,
as well as an additional trend toward a negative associ-
ation with tumour stage, were detected (Figure 3A-C).
This result was confirmed by investigating whether cyto-
plasmic Bcl-3 cancer cells are proliferative or apoptoticcells. Immunohistochemistry staining using freshly iso-
lated CRC showed that Ki-67 but not cleaved Caspase 3
positive cells express Bcl-3 in the cytoplasm (Figure 4).
These results suggest that in CRC, the majority of prolifer-
ative cancer cells express Bcl-3 in the cytoplasm, whereas
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Figure 3 Correlation between nuclear fraction of Bcl-3 (continuous) and (A) node stage (r = −0.189, p = 0.002), (B) tumour stage (r = −0.100,
p = 0.108), and (C) nuclear fraction of the proliferation marker Ki67 (r = 0.177, p = 0.004).
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colon cancer, we prepared total cell lysate from SW-48,
HT-29, SW-480, CACO-2, HCT-116 and LOVO and
found variation in Bcl-3 expression in these cell lines.
High expression of Bcl-3 was detected in CACO-2,
HCT-116 and LOVO, while SW-48, HT-29 and SW-480
cells showed lower Bcl-3 expression (Figure 5A). To in-
vestigate Bcl-3 localization in colon cancer cell lines, we
performed biochemical cell fractionation and immuno-
fluorescence staining. We successfully purified nuclei
and cytoplasm using cell fractionation (Figure 5B, see
tubulin and lamin B) and found that under basal condi-
tions the majority of Bcl-3 is expressed in the cytoplasm
compared with a low level of Bcl-3 in the nucleus
(Figure 5B). To confirm this result, we performed im-










Figure 4 Immunohistochemical sample images with IHC staining represen
Ki67 or cleaved Caspase 3, respectively.of Bcl-3 localization in CACO-2, HCT-116, and
breast cancer cell line MCF-7 and showed the accu-
mulation of Bcl-3 in the cytoplasm of CACO-2 and
HCT-116 but not in MCF-7 cells (Figure 5C). These
results suggest that cytoplasmic localization of Bcl-3
is specific to colon cancer compared to breast cancer
cell lines. Previously, we could demonstrate re-localization
of Bcl-3 in mouse keratinocytes upon TPA treatment
[13,21]. To investigate whether we can observe similar
translocation of Bcl-3, colon cancer cell line were stimu-
lated with TPA for 30 minutes. No differences in the
localization of Bcl-3 comparing TPA stimulated with non-
stimulated CACO-2 or HCT-116 cells could be detected
(Figure 5C). Can sustained Wnt signalling affect Bcl-3
localization? To test this hypothesis, we used human


































































Figure 5 Expression and localization of Bcl-3 in colon cancer cell lines. Total cell lysate of indicated colorectal cell lines was analysed by Western
blot for Bcl-3 and actin (A). Subcellular fractions of LOVO, HCT-116 and CACO-2 were prepared. Nuclear and cytosol fractions were analysed by
immunoblotting (B). CACO-2, HCT-116, and MCF-7 cells were analysed with immunofluorescence towards Bcl-3. When indicated cells were
stimulated with 100 nM TPA. DAPI was used as a nuclear marker. Cells were examined with confocal microscopy (C). Whole cell lysates of the
indicated colon cancer cell lines grown in complete medium were subjected to Western blotting (D).
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APC [22]. In this cell line the levels of Bcl-3 were un-
detected (Figure 5D).
Discussion
The proto-oncogene Bcl-3 is known to be overexpressed
and localized in the nuclei of different solid tumours
such as breast [7], nasopharyngeal [8], endometrial [9]
and prostate cancer [11]. However it is not known
whether localization of Bcl-3 in colon cancer is similar
to other reported studies, and whether localization of
Bcl-3 has any prognostic value in colon cancer. In the
present study, we investigated whether localization of
Bcl-3 in cancer cells follows the same pattern as in pre-
viously reported solid tumours. Surprisingly, we found
that in freshly isolated colon biopsies Bcl-3 was localizedin the cytoplasm of the cancer tissues, while non-
cancerous tissue showed an accumulation of Bcl-3 in the
nuclei. These results were confirmed by analysing Bcl-3
localization in a cohort of patients with CRC, in which
significant differences in the localization of Bcl-3 be-
tween normal tissue and invasive tumours were ob-
served. Cancer cells showing cytoplasmic localization
of Bcl-3 were also positive for the proliferation marker
Ki67 but not for the apoptotic marker Caspase 3. This
suggests that preventing nuclear localization of Bcl-3
in colon cancer cells facilitates proliferation of these
cells. In addition, we found cytoplasmic localization of
Bcl-3 in three human colon cancer cell lines, confirm-
ing the results obtained from our freshly isolated tis-
sues and TMA analysis. A shift from positive Bcl-3
staining in the nucleus to the cytoplasm could indicate
Saamarthy et al. BMC Cancer  (2015) 15:341 Page 8 of 9the transition of normal colonic epithelia cells into
colon cancer.
The role of Bcl-3 in colon cancer is not yet known. A
recent retrospective study of 23 patients who underwent
surgical resection of CRC showed that nuclear expres-
sion of p50, p65 and Bcl-3 is negatively associated with
survival [10]. Furthermore, dose-dependent inhibition of
COX-2 using NS398 inhibited the expression of Bcl-3
and cyclin D1 in a human colon cancer cell line [23]. In
mice, deletion of Bcl-3 protected against chemically-
induced colitis compared to wild-type animals. This
treatment also resulted in elevated intestinal epithelial
cell proliferation in Bcl-3 knockout mice compared with
the control, suggesting that Bcl-3 plays a major role in
regulating proliferation and sensitivity to chemically
induced colitis. Furthermore, Bcl-3 expression in the
colon of inflammatory bowel disease (IBD) patients was
significantly increased compared to healthy individuals
[24].
Bcl-3 can be localized both in the cytoplasm and
nucleus dependent on the cell type or stimuli. Two
mechanisms for Bcl-3 nuclear transport have been iden-
tified. Bcl-3 contains a classical nuclear localization
signal (NLS) within its N-terminal domain and thus can
be imported into the nucleus [25]. Post-translational
modification of Bcl-3 via ubiquitination was also shown
to be essential for nuclear localization of Bcl-3. The
nuclear translocation of Bcl-3 is blocked by the de-
ubiquitination enzyme CYLD via direct interaction and
removal of K63-linked polyubiquitin chains from Bcl-3
[13,14]. The mechanism that promotes cytoplasmic re-
tention of Bcl-3, which we observed in normal colonic
epithelia cells, is not known. In the nucleus Bcl-3 can
initiate or repress the transcription of target genes
[11,26]. Future studies are needed to identify the mechan-
ism and signaling pathway that hold Bcl-3 in the cyto-
plasm of colon cancer cells.
Conclusions
In summary, we identified a potential role of Bcl-3 in
colorectal cancer through its localization in cells and tis-
sue samples. In the cancer tissues or cells Bcl-3 was local-
ized in the cytoplasm, while non-cancerous tissue/cells
showed an accumulation of Bcl-3 in the nuclei. This find-
ing implies that Bcl-3 could serve as an early diagnostic
marker in colorectal cancer.
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